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Background: Celiac disease (CD) is a chronic disorder in genetically predisposed individuals in which a small
intestinal immune-mediated enteropathy is precipitated by dietary gluten. It can be difficult to diagnose because
signs and symptoms may be absent, subtle, or not recognized as CD related and therefore not prompt testing
within routine clinical practice. Thus, most people with CD are undiagnosed and a public health intervention, which
involves screening the general population, is an option to find those with unrecognized CD. However, how these
screening-detected individuals experience the diagnosis and treatment (gluten-free diet) is not fully understood.
The aim of this study is to investigate the health-related quality of life (HRQoL) of adolescents with screening-
detected CD before and one year after diagnosis and treatment.
Methods: A prospective nested case-referent study was done involving Swedish adolescents who had participated
in a CD screening study when they were in the sixth grade and about 12 years old. Screening-detected adolescents
(n = 103) and referents without CD who participated in the same screening (n = 483) answered questionnaires at
the time of the screening and approximately one year after the screening-detected adolescents had received their
diagnosis that included the EQ-5D instrument used to measure health status and report HRQoL.
Results: The HRQoL for the adolescents with screening-detected CD is similar to the referents, both before and
one year after diagnosis and initiation of the gluten-free diet, except in the dimension of pain at follow-up. In the
pain dimension at follow-up, fewer cases reported problems than referents (12.6% and 21.9% respectively, Adjusted
OR 0.50, 95% CI 0.27-0.94). However, a sex stratified analysis revealed that the significant difference was for boys at
follow-up, where fewer screening-detected boys reported problems (4.3%) compared to referent boys (18.8%)
(Adjusted OR 0.17, 95% CI 0.04-0.73).
Conclusions: The findings of this study suggest that adolescents with unrecognized CD experience similar HRQoL
as their peers without CD, both before and one year after diagnosis and initiation of gluten-free diet, except for
boys in the dimension of pain at follow-up.
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Celiac disease (CD) is a chronic disorder in genetically
predisposed individuals in which a small intestinal
immune-mediated enteropathy is precipitated by dietary
gluten [1]. The prevalence has generally been suggested
to be around 1% [2-4], however more recently it has
been shown that the prevalence has risen [3,5,6] and
most of the people with CD are actually undiagnosed
[7-10]. CD can be difficult to diagnose because the signs
and symptoms may be absent, subtle, or not recognized
as CD related and therefore not prompt testing within
routine clinical practice [11]. The best strategy for
finding those with unrecognized CD is still debated, but
options include: active case finding through routine
clinical practice with a broader consideration for variety
in presentation, testing groups at high risk (e.g., first
degree relatives of those with CD or those with other
autoimmune disorders), or a public health intervention
that would involve screening the general population
[3,7,10,12,13].
Recently, Aggarwal et al. presented a review of litera-
ture that addresses how screening, diagnosing, and
treating (gluten-free diet) asymptomatic individuals af-
fects their quality of life [3]. Their overview illustrates
that there is a lack of consensus on whether or not the
gluten-free diet (GFD) improves the quality of life in
“asymptomatic screening-detected” individuals [3]. Re-
search addressing the quality of life (QoL) and health-
related quality of life (HRQoL) for people with CD is
mostly based on those diagnosed through routine clin-
ical practice or selected for screening because they are
considered at high risk [14-28]. The HRQoL for
individuals who have received their CD diagnosis from a
screening of the general population could differ from
these groups and this study focuses on adolescents
diagnosed with CD as a result of screening study. The
aim of this study is to investigate the HRQoL of
adolescents with screening-detected CD before and one
year after diagnosis and treatment.
Method
Design
A prospective nested case-referent study was done involv-
ing adolescents who had participated in a CD screening
study. The cases included those with screening-detected
CD and referents were chosen from those who tested
negative for the CD serological markers. The cases and
referents reported their HRQoL at the time of the
screening and about one year after the cases received
their diagnosis.
Setting
The CD screening study that the adolescents participated
in (ETICS-Exploring the Iceberg of Celiacs in Sweden)took place in 2005–2006 [8]. It involved sixth graders
from 5 regions in Sweden when they were about 12 years
old. The screening took place in their schools in collabor-
ation with school health systems and regional pediatric
departments. Information was provided to parents and
children, written consent was obtained from parents, and
ethical approval for the study was granted by the Regional
Ethical Review board in Umea, Sweden [Dnr UMU
04-156-M].Participants and materials
In total, 10 041 children were invited and 7 567 (75%)
consented to participate. Blood samples were collected
from 7 208 (72%) children who did not already have a
CD diagnosis. The blood samples were analyzed for CD
serological markers and children with suspected CD
were referred to their pediatric department for an intes-
tinal biopsy to confirm the diagnosis [8]. Thereafter, a
GFD was recommended and follow-up care was
provided according to current clinical standards.
At the time the population for this study was selected,
there were 145 children with screening-detected/biopsy
verified CD and 62 who reported having CD diagnosed
prior to the screening and gave a blood sample. After
combining these groups with CD (n = 207), 4 referents
per child were randomly chosen (n = 828), with the pro-
portion of girls and boys in the referent group to match
that of the group with CD. From the 207 children with
CD, 2 were found to be without CD, resulting in 61
diagnosed prior to the screening and 144 screening-
detected cases (Figure 1).
The participants filled out questionnaires that included
the Swedish child-friendly pilot version of the EQ-5D in-
strument (EQ-5D) [29-31]. The EQ-5D is a generic tool
used to measure health status and report HRQoL [32]. It
is comprised of two parts, the EQ-5D descriptive system
where respondents classify their health status in five
dimensions: mobility, self-care, usual activities, pain/dis-
comfort, and anxiety/depression and on level of severity
(no problems, moderate problems, or severe problems).
The second part of the EQ-5D is a thermometer like vis-
ual analogue scale (VAS) where respondents score their
health today from worst to best imaginable (0–100)
[32,33].
After blood samples were collected, but before the results
of the screening were known, the 12-year-olds were given
the questionnaires to fill out at school. Baseline EQ-5D
responses were received from 138 with screening-detected
CD (96% responding) and 797 referents (96% responding).
Approximately one year after the screening, follow-up
questionnaires were mailed to the homes of those
considered cases and referents for this nested-case referent
study. Follow-up EQ-5D responses were received from 110
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referents (61% responding).
Responses were included for the screening-detected
cases and referents when they had provided answers for
all five dimensions and on the VAS at both baseline and
follow-up (cases n = 103 and referents n = 483) (Figure 1).
The median age of the cases at the time of the diagnostic
biopsy was 13.2. Because the participants answered the
questionnaires approximately one year after the cases
had received the diagnosis their median age was 14.6
and we consider them adolescents at follow-up.
Analysis
Number and proportion of adolescents reporting
problems were explored for each dimension. Because
few adolescents reported severe problems, levels of se-
verity were collapsed into “no problems” (from level no
problems) and “problems” (from levels some problems
and severe problems) [33]. The statistical software pack-
age SPSS 19 (SPSS Inc., Chicago, IL) was used and stat-
istical significance was defined at the 5% level.
Cross tabulations were done separately for each di-
mension and for baseline and follow-up to illustrate the
proportion reporting problems. Bivariate logistic regres-
sion was used to compare the proportion reporting
problems for the cases and referents separately at base-
line and follow-up, and between the cases and referents
at baseline and follow-up, for each dimension. Then, in
order to assess and compare crude and adjusted odds
ratios (OR) and confidence intervals (CI), multivariate
logistic regression analyses were also performed for each
dimension. In the logistic regression models, case/
referent was the dependent variable and problems atbaseline and problems at follow-up were independent
variables, separately for the bivariate analyses (Crude
OR) and combined in the same model for the multivari-
ate analyses (Adjusted OR). Sex stratified analyses were
done for the pain and anxiety dimension, however not
for the other dimensions as there were too few reporting
problems to motivate further exploration.
The VAS scores of the cases and referents, and the
VAS scores for boys and girls within the case and
referent groups, were compared using the Mann–
Whitney U test. When we compared baseline to follow-
up scores in the case and referent groups we used the
Wilcoxon signed rank test.
Results
The HRQoL for the adolescents with screening-detected
CD, as reported on the EQ-5D instrument, is similar to
the HRQoL of the referents, both before and one year
after diagnosis and initiation of the GFD, except for in
the dimension of pain at follow-up, where fewer cases
reported problems than referents (12.6% and 21.9% re-
spectively, Adjusted OR 0.50, 95% CI 0.27-0.94) (Table 1).
However, when this dimension was stratified by sex, it
was revealed that the difference was between boy cases
and referents at follow-up. In the sex stratified results
there was a significant difference between the boys in
the pain dimension at follow-up, where fewer of the
screening-detected boys reported problems (4.3%) than
the boy referents (18.8%) (Adjusted OR 0.17, 95% CI
0.04-0.73) (Table 2).
In the anxiety dimension, both the cases and referents
had an increase (from baseline to follow-up) in the pro-
portion of adolescents who reported problems, although
Table 1 Adolescents reporting problems (EQ-5D), before and 1 year after screening-detected celiac disease diagnosis,




Screening-detected CD (cases n = 103) Non CD (referents n = 483) Odds Ratios (95% CI)a
n (%) with problems n (%) with problems Bivariate LRb Multivariate LRc
Mobility
Baseline 3 (2.9) 11 (2.3) 0.78 (0.21-2.84) 1.28 (0.35-4.68)
Follow-up 1 (1.0) 7 (1.4) 0.67 (0.08-5.48) 0.67 (0.08-5.52)
Self care
Baseline 0 0 2 (0.4) 0.00 (0.00-) 0.00 (0.00-)
Follow-up 0 0 2 (0.4) 0.00 (0.00-) 0.00 (0.00-)
Activity
Baseline 3 (2.9) 13 (2.7) 0.92 (0.26-3.30) 1.09 (0.31-3.91)
Follow-up 2 (1.9) 11 (2.3) 0.85 (0.19-3.89) 0.85 (0.18-3.88)
Pain
Baseline 21 (20.4) 95 (19.7) 0.96 (0.56-1.62) 1.18 (0.69-2.02)
Follow-up 13 (12.6) 106 (21.9) 0.51 (0.28-0.96) 0.50 (0.27-0.94)
Anxiety/Depression
Baseline 13 (12.6) 52 (10.8) 0.84 (0.44-1.60) 1.37 (0.70-2.69)
Follow-up 15 (14.6) 95 (19.7) 0.70 (0.39-1.26) 0.65 (0.35-1.20)
a Odds ratio (95% confidence interval).
b Bivariate logistic regression using case/referent and problems reported.
c Multivariate logistic regression using case/referent and problems reported at baseline and problems reported at follow-up.
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stratified by sex, there was no significant difference in
proportion of problems reported for anxiety for the boys
or girls between the cases and referents (Table 3).
Adolescents with screening-detected CD had a median
VAS score of 91 at baseline and 90 at follow-up (Table 4),
which was not a significant change (Wilcoxon signed
rank test, p value = 0.92). The referents median VASTable 2 Total adolescents, boys, and girls reporting problems
screening-detected celiac disease diagnosis, compared to refe
Groups at Baseline
and Follow-up
Screening-detected CD (cases) No
n (%) with problems n
Total n = 103 n
Baseline 21 (20.4) 95
Follow-up 13 (12.6) 10
Boys n = 47 n
Baseline 13 (27.7) 41
Follow-up 2 (4.3) 39
Girls n = 56 n
Baseline 8 (14.3) 54
Follow-up 11 (19.6) 67
a Odds ratio (95% confidence interval).
b Bivariate logistic regression using case/referent and problems reported.
c Multivariate logistic regression using case/referent and problems reported at basescore was 90 at baseline and at follow-up (Table 4).
Comparisons of cases to referents at baseline and at
follow-up showed no significant differences (Mann–
Whitney U test, not shown).
When comparing boys and girls within the case and
referent groups, the only significant difference was be-
tween the boys and girls in the referent group at follow-
up (Mann–Whitney U test, p value = 0.01, not shown),in pain dimension (EQ-5D), before and 1 year after
rents without celiac disease
n CD (referents) Odds Ratios (95% CI)a
(%) with problems Bivariate LRb Multivariate LRc
= 483
(19.7) 0.96 (0.56-1.62) 1.18 (0.69-2.02)
6 (21.9) 0.51 (0.28-0.96) 0.50 (0.27-0.94)
= 208
(19.7) 1.56 (0.76-3.22) 1.90 (0.90-4.03)
(18.8) 0.19 (0.05-0.83) 0.17 (0.04-0.73)
= 275
(19.6) 0.68 (0.31-1.53) 0.72 (0.32-1.62)
(24.4) 0.76 (0.37-1.55) 0.81 (0.39-1.67)
line and problems reported at follow-up.
Table 3 Total adolescents, boys, and girls reporting problems in anxiety dimension (EQ-5D), before and 1 year after
screening-detected celiac disease diagnosis, compared to referents without celiac disease
Groups at Baseline
and Follow-up
Screening-detected CD (cases) Non CD (referents) Odds Ratios (95% CI)a
n (%) with problems n (%) with problems Bivariate LRb Multivariate LRc
Total n = 103 n = 483
Baseline 13 (12.6) 52 (10.8) 0.84 (0.44-1.60) 1.37 (0.70-2.69)
Follow-up 15 (14.6) 95 (19.7) 0.70 (0.39-1.26) 0.65 (0.35-1.20)
Boys n = 47 n = 208
Baseline 4 (8.5) 16 (7.7) 1.12 (0.36-3.51) 1.46 (0.43-4.95)
Follow-up 2 (4.3) 18 (8.7) 0.47 (0.11-2.10) 0.41 (0.08-1.98)
Girls n = 56 n = 275
Baseline 9 (16.1) 36 (13.1) 1.27 (0.57-2.81) 1.38 (0.61-3.13)
Follow-up 13 (23.2) 77 (28.0) 0.78 (0.40-1.53) 0.73 (0.37-1.47)
a Odds ratio (95% confidence interval).
b Bivariate logistic regression using case/referent and problems reported.
c Multivariate logistic regression using case/referent and problems reported at baseline and problems reported at follow-up.
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and girls the 25th percentile is 85 and 75 (respectively)
and the 75th percentile is 98.75 and 97 (respectively).Discussion
The HRQoL for adolescents with screening-detected
CD, as self-reported on the EQ-5D, is similar to that of
their peers, both before and one year after diagnosis and
GFD, except in the dimension of pain at follow-up. A
sex stratified analysis revealed that this is due to the dif-
ference between boy cases and referents at follow-up, in
which 4.3% of the screening-detected boys report
problems and 18.8% of the referent boys report
problems (Adjusted OR 0.17, 95% CI 0.04-0.73)
(Table 2).
We present a unique study in which adolescents with
screening-detected CD report their HRQoL before and
one year after diagnosis and treatment. A strength of
our study is that the adolescents report baseline HRQoL
before knowledge of their CD diagnosis, unlike many
studies in which patients are asked to recall how they
felt at the time of their diagnosis. We have previously
published baseline data, including participants from the
same screening study, in which there was also no signifi-
cant difference in HRQoL for those with unrecognizedTable 4 VAS scores of adolescents, before and 1 year
after screening-detected celiac disease diagnosis,






Screening-detected CD (cases) Non CD (referents)
n = 103 n = 483
Median Quartiles Median Quartiles
25th, 75th 25th, 75th
Baseline 91 85, 97 90 80, 99
Follow-up 90 80, 99 90 80, 98CD compared to their peers without CD at the time of
the screening [34]. However, in this current study we ex-
plore the adolescents’ HRQoL before and after diagnosis
and treatment.
Another strength of this study is the fact that the
adolescents had their CD detected as a result of a
screening study, and not clinically or because they
were considered high risk. This means that our
results may be more reflective of those living with
unrecognized CD, which has been seen as a limitation
in other studies that attempt to address the QoL for
those with undiagnosed CD [3]. In a review of litera-
ture that addresses how screening, diagnosing, and
treating “asymptomatic screening-detected individuals”
affects their QoL, done by Aggarwal et al. [3], most
of the studies involved CD patients who were identi-
fied from high risk groups [19,26] or were compared
based on what type of symptoms led to their diagno-
sis; i.e., typical, not typical, or those who reported
they had not experienced any symptoms [23,24,28].
However, two of the studies included individuals that
could be considered as screened from the general
population [3,35,36]. In those studies, the individuals
who had “typical” symptoms showed an improvement
in QoL scores after one year on the GFD, while those
who were supposedly symptom free had scores compar-
able to healthy controls at baseline and at follow-up,
[35,36] similar to the screening-detected adolescents in
our study.
Even though the EQ-5D instrument is a validated tool
and we have used the Swedish child-friendly pilot ver-
sion, this tool may have limitations in the context of this
study. Perhaps, it is not the ideal tool for capturing
problems with subtle symptoms or feelings caused by
unrecognized CD. Also, these adolescents may have
adapted to their current health situation as normal and
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and similar to their peers. If they did experience im-
provement after diagnosis and treatment, they would be
unable to demonstrate improvement from the high
health status previously reported. These screening-
detected adolescents were also invited to participate in
another follow-up study, where they participated in
focus group discussions (n = 31) and wrote narratives
(n = 91), and when they were asked specifically about
change in well-being after diagnosis, 53.8% reported
feeling better [37]. In that study, it was also shown that
some of the screening-detected children only realized
they had been experiencing symptoms after they had
been diagnosed and treated [37].
Although it is beyond the scope of this study to pro-
vide an explanation, the finding that fewer screening-
detected boys (4.3%) reported problems at follow-up in
the dimension of pain than the boy referents (18.8%) is
interesting to consider and warrants further investiga-
tion. In a previous Swedish study, a doubled risk for
symptomatic CD in girls compared to boys was found
[38]. In this screening study, the male to female ratio for
those with clinically diagnosed CD was 1:2 compared to
1:1 for those with screening-detected CD [8]. This differ-
ence reveals that, at the time of the screening, a larger
proportion of girls compared to boys had already been
diagnosed with CD in routine clinical practice [8]. It
could be that the boys with unrecognized CD were fur-
ther progressed in their disease at baseline because they
were not as likely as the girls to have been found in clin-
ical practice. One could speculate that, even though
they may not have realized the extent of their
problems at baseline, they experienced benefit from
the treatment resulting in fewer of these boys
reporting problems with pain than the boys in the
referent group, a phenomenon which was not
captured for the girls. In studies involving adults,
men and women have been shown to experience the
burden of CD differently [27,39,40]. There is also re-
search that shows men and women access health care
differently [41-43] and perhaps the boys were less
likely to seek or receive care. It is also a possibility
that clinicians expect girls to have a higher risk of
developing CD and more readily recognize and diag-
nose girls.
In our study there were no significant differences in the
anxiety dimension between cases and referents, suggesting
that for these screening-detected adolescents the CD diag-
nosis and GFD have not caused excess anxiety (at least at
one year follow-up). Other studies have shown that
those with a strict GFD can have the same HRQoL
as healthy children/adolescents [44,45]. However, in
the qualitative study mentioned previously [37], it was
revealed that some of these adolescents perceivedthe GFD and lifestyle changes as inconvenient and
causing feelings of stigma while others adapted well
to the disease.
Conclusions
The findings of this study suggest that the adolescents
with unrecognized CD experience similar HRQoL as
their peers without CD, both before and one year after
the diagnosis and initiation of the GFD, except for boys
in the dimension of pain at follow-up. The screening-
detected boys seem to benefit, because fewer report
problems with pain than the boy referents at follow-up,
one year after diagnosis and initiation of the GFD. How-
ever, further research is needed to explore why the
screening-detected boys seem to have a different experi-
ence from the referent boys and from the screening-
detected girls. If considering general population
screening for CD in the future, more research is also
needed to learn more about the benefits or drawbacks of
early diagnosis, long term consequences of untreated
CD, and the health economic implications of population
screening.
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